Dahan R, Costantini D, Caulin C, Yagello M
Methods Find Exp Clin Pharmacol. 1986 Jan;8(1):41-3.
C 1740 is an immunmodulating agent of biological origin proposed for the prevention of infectious exacerbations in chronic bronchopathy. The first placebo-controlled double-blind randomized clinical trials have led to opposite conclusions regarding the utility of C 1740. The rate of infectious exacerbations in the placebo group and a large Type II error could explain the "negative clinical trials". However, two out of four "positive clinical trials" were associated with high risk of falsely positive results. The activity of C 1740 is discussed here.
C 1740是一种具有生物来源的免疫调节药物，旨在预防慢性支气管病的感染性加重。首批安慰剂对照双盲随机临床试验就C 1740的效用得出了相反结论。安慰剂组的感染性加重率以及较大的II类错误可能解释了这些“阴性临床试验”。然而，四项“阳性临床试验”中有两项存在假阳性结果的高风险。本文讨论了C 1740的活性。
